Biopharma Patients Physicians Prescription 
PM360
JULY 21, 2022
As pharma reps’ access to physicians continues to decline, this case study examines the effectiveness of reaching physicians through other means—the EHR. Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks.
Clarivate
DECEMBER 14, 2021
As the COVID-19 pandemic continues to evolve, we are seeing substantial shifts in the way patients access healthcare and how providers deliver care. 2021 surveys of patients and physicians in the United States conducted by Clarivate show that: Much of care delivery has gone virtual. hours seeing patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
OCTOBER 25, 2023
While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs. With 27.5% exclusions exist for orphan drug designation and biosimilar competition ).
Clarivate
APRIL 18, 2024
While the key players’ strategies differ, all are focused on bending the cost curve while increasing patient touchpoints and engagement. RxPass offers more than 50 select prescriptions at no additional cost for $5 per month.
Pharmaceutical Technology
SEPTEMBER 8, 2022
Speciality pharmacies play a crucial role in medication dosing, disease and side effects management, and patient care. The expert services rendered by them help in improving patient outcomes, minimising costs of the healthcare system, improving medicinal adherence and persistency and saving clinicians’ time.
Clarivate
JULY 5, 2023
biologics market and reduce prescription drug costs. and European physicians across six specialties, and global pipeline analysis curated by experts to provide insights into the evolving landscape. By end of year, as many as ten adalimumab biosimilars could be on the U.S. In 2022, it made its manufacturer, AbbVie, $21.2bn.
Eversana Intouch
FEBRUARY 23, 2023
Historically, the pharmaceutical industry is economically sturdy, but three things are not: patients’ household budgets, marketing department budgets, and small-company budgets. Biopharma valuations are down, especially for public and earlier-stage companies. Implications of economic volatility abound: Patients: Market access gaps.
Expert insights. Personalized for you.
52 
Let's personalize your content